Effect of randomised blood pressure lowering treatment and intensive glucose control on dementia and cognitive decline according to baseline cognitive function and other subpopulations of individuals with type 2 diabetes: Results from the ADVANCE trial

作者：Katie Harris, Jessica Gong, Stephen MacMahon, Ying Xu, Sultana Shajahan, Stephen Harrap, Neil Poulter, Michel Marre, Pavel Hamet, G. Mancia, Craig S. Anderson, Mark Woodward, John Chalmers · 发表于：Cerebral Circulation - Cognition and Behavior · 年份：2024 · DOI：10.1016/j.cccb.2024.100372 · 被引用次数：2 · 研究领域：Dementia and Cognitive Impairment Research、Neurological Disease Mechanisms and Treatments、Alzheimer's disease research and treatments

• In a study of over eleven thousand participants with Type 2 Diabetes, blood pressure lowering treatment (vs. placebo) was associated with a lower odds of dementia/cognitive decline in people with mild-severe cognitive impairment but not in those with normal cognition • Those with impaired glucose at baseline favoured intensive glucose control, though for those with normal glucose at baseline showed a tendency for standard control on the odds of dementia/ cognitive decline • For those with less than 10 years diabetes duration there was a tendency to favour intensive control and the converse for those with longer diabetes duration on the odds of dementia/ cognitive decline . : Accumulating evidence indicates that reducing high blood pressure (BP) prevents dementia and mild cognitive impairment (MCI). Furthermore, although diabetes is a risk factor for dementia and MCI, there is uncertainty of the effect of intensive glucose control on these endpoints. This study aimed to determine the effects of BP-lowering (vs placebo) and intensive glucose-lowering (vs standard control) treatments according to baseline cognition and other characteristics on dementia and cognitive decline (CD) in people with type 2 diabetes mellitus (T2DM). : The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial involved 11,140 individuals with T2DM. The effects of BP-lowering and intensive glucose-lowering treatments were explored in subgr...